Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2565-2569

  Campione, Elena ^a   Diluvio, Laura ^a   Paternò, Evelin J ^a   Di Marcantonio, Dely ^a   Francesconi, Arianna ^a   Terrinoni, Alessandro ^a   Orlandi, Augusto ^a   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

cutaneous Kaposi's sarcoma; HHV8; HIV; imatinib

Indexed keywords

BCR ABL PROTEIN; IMATINIB; VIRUS DNA;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; MALE; MOLECULAR BIOLOGY; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; PUNCH BIOPSY; SKIN DEFECT;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; DNA, VIRAL; FUSION PROTEINS, BCR-ABL; HERPESVIRUS 8, HUMAN; HIV SERONEGATIVITY; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, KAPOSI; SKIN;

EID: 74549196558     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.018     Document Type: Article

References (22)

1. Danzig J.B., Brandt L.J., Reinus J.F., and Klein R.S. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol. 86 (1991) 715-718
2. Zinberg J., Chernaik R., Coman E., et al. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol. 86 (1991) 1251-1254
3. Schalling M., Ekman M., Kaaya E.E., et al. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat Med. 1 (1995) 707-708
4. Chang Y., Cesarman E., Pessin M.S., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266 (1994) 1865-1869
5. Hengge U.R., Ruzicka T., Tyring S.K., et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis. 2 (2002) 281-292
6. Gao S.J., Kingsley L., Li M., et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 2 (1996) 925-928
7. Giuliani M., Cordiali-Fei P., Castilletti C., et al. Incidence of human herpesvirus 8 (HHV-8) infection among HIV-uninfected individuals at high risk for sexually transmitted infections. BMC Infect Dis. 7 (2007) 143
8. Panayiotakopoulos G.D., Mavroyianni D., Politou M., et al. Human herpesvirus-8 seropositivity and clinical correlations in HIV-1-positive and highly exposed, persistently HIV-seronegative individuals in Greece. AIDS Patient Care STDS. 19 (2005) 375-383
9. Schwartz R.A. Kaposi's sarcoma: An update. J Surg Oncol. 87 (2004) 146-151
10. Moses A.V., Jarvis M.A., Raggo C., et al. Kaposi's sarcomaassociated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol. 76 (2002) 8383-8399
11. In: Burns T., Breathnach S., Cox N., and Griffiths C. (Eds). Rook's Textbook of Dermatology. 7th ed. (2004), Blackwell Publishing, Malden, Mass
12. Gill P.S., Loureiro C., Bernstein-Singer M., et al. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 110 (1989) 937-940
13. Pantanowitz L., Fruh K., Marconi S., et al. Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol. 8 (2008) 7
14. Gérard L., Bérezné A., Galicier L., et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol. 25 (2007) 3350-3356
15. Koon H.B., Bubley G.J., Pantanowitz L., et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 23 (2005) 982-989
16. Anderson L.A., and Goedert J.J. Tumor markers and treatments for Kaposi sarcoma. AIDS. 21 (2007) 1637-1639
17. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
18. Druker B.J., Guilhot F., O'Brien S.G., et al., IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med. 355 (2006) 2408-2417
19. Ou J., Vergilio J.A., and Bagg A. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol. 83 (2008) 296-302
20. Basciani S., Vona R., Mattarrese P., et al. Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells [published correction appears in FEBS Lett. 2008;582:398]. FEBS Lett. 581 (2007) 5897-5903
21. Abruzzese E., Cantonetti M., Morino L., et al. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: Two case reports. J Clin Oncol. 21 (2003) 4256-4258
22. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 30 (1981) 239-245